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ABSTRACT 
Human colon carcinoma cells (HCT116) differing in p53 status were exposed to 
benzo(a)pyrene (BaP) or anti-benzo(a)pyrene-trans-7,8-dihydrodiol-9,10-epoxide (BPDE), 
and their gene expression responses compared by cDNA microarray technology. Exposure of 
cells to BPDE for up to 24 h resulted in gene expression profiles more distinguishable by 
duration of exposure than by p53 status, although a sub-set of genes were identified that had 
significantly different expression in p53-wild type (WT) cells relative to p53-null cells. 
Apoptotic signalling genes were up-regulated in p53-WT cells but not in p53-null cells and, 
consistent with this, reduced viability and caspase activity were also p53-dependent. BPDE 
modulated cell cycle and histone genes in both cell lines and, in agreement with this, both cell 
lines accumulated in S-phase. In p53-WT cells, G2 arrest was also evident, which was 
associated with accumulation of CDKN1A. Regardless of p53 status, exposure to BaP for up 
to 48 h had subtle effects on gene transcription and had no influence on cell viability or cell 
cycle. Interestingly, DNA adduct formation after BaP, but not BPDE, exposure was p53-
dependent with 10-fold lower levels detected in p53-null cells. Other cell lines were 
investigated for BaP-DNA adduct formation and in these the effect of p53 knock-down was 
also to reduce adduct formation. Taken together these results give further insight into the role 
of p53 in the response of human cells to BaP and BPDE and suggest that loss of this tumour 
suppressor can influence the metabolic activation of BaP.  
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INTRODUCTION 
The p53 tumour suppressor functions as a key player in determining cell fate after occurrence 
of various types of DNA damage and its gene is mutated in more than 50% of human tumours 
[1]. Upon genotoxic stress, cellular levels of p53 protein increase via post-transcriptional 
mechanisms [2] and the ability of p53 to bind specific DNA sequences is activated. Induction 
of p53 in response to DNA damage has been suggested as a means of genotoxicity testing 
[3,4]. Transcriptional modulation of p53-target genes leads to the regulation of downstream 
cellular processes, primarily cell-cycle arrest, apoptosis and DNA repair, that protect the cell 
from DNA damage and transformation [2,5].  
Benzo(a)pyrene (BaP), a carcinogenic polycyclic aromatic hydrocarbon (PAH), exerts 
its genotoxic effects through metabolic bioactivation to anti-benzo(a)pyrene-trans-7,8-
dihydrodiol-9,10-epoxide (BPDE), which binds covalently to DNA [6]. There is strong 
evidence linking this DNA damage directly with carcinogenesis [7]. For example, the 
distribution of BPDE-DNA adducts along the p53 gene in cultured cells strongly correlated 
with p53 mutation sites of human lung cancers [7-9]. In addition, the expression of p53 and 
one of its major transcriptional targets, CDKN1A (p21), after exposure to BaP, has been 
found to correlate with DNA adduct formation in human lung diploid fibroblasts [10]. The 
importance of p53 in cellular protection against tumourigenesis is highlighted by studies in 
mice with a mutated p53 genotype in which carcinogens induce more tumours than in mice 
expressing wild-type (WT) p53 [11,12].  
The accumulation of p53 after carcinogen exposure has been observed in many studies 
and in a recent one, in which we analysed gene expression changes induced in cultured human 
cells exposed to BaP, we found that p53 plays an important role in this transcriptional 
response [13]. In another study [14] gene expression profiles of cells differing in p53 status 
were compared after exposure to genotoxic and non-genotoxic agents. p53-dependent gene 
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expression was identified for the genotoxic, but not for the non-genotoxic, agents, although 
PAHs were not included in this study. To investigate further the role of p53 in the cellular 
response to BaP we have analysed a pair of human colorectal cell lines (HCT116) that differ 
in p53 status (i.e. WT and knock-out) after exposure to BaP or BPDE. In addition, other 
biological parameters were investigated including DNA adducts, cell cycle, and protein 
expression. Expression changes together with biological outcomes were identified in cells 
exposed to BPDE that were dependent or independent of p53 status. DNA adduct formation 
by BaP was p53-dependent, with 10-fold lower adduct levels detected in p53-null cells. The 
influence of p53 expression on BaP-DNA adduct formation in other cell lines with partial 
knock-down of p53 function, confirmed that loss of p53 in vitro has effects on the metabolic 
activation of BaP. 
 
MATERIALS AND METHODS 
Cell culture and chemical treatment 
The HCT116 human colorectal carcinoma cell line pair [15], one expressing wild-type p53 
(p53-WT) and one with complete knock-out of p53 (p53-null), were kindly provided by 
Professor Bert Vogelstein, Johns Hopkins University School of Medicine, Baltimore MD. 
Stable shRNA p53-knock-down A549 human lung carcinoma cells and empty vector control 
cells were kindly provided by Mr Gunnar Jahnke and Professor Andrea Hartwig (Technical 
University of Berlin, Germany). Details concerning the construction and characterisation of 
the p53 knock-down A549 cell line will be published elsewhere (G. Jahnke and A. Hartwig, 
in preparation). Briefly, A549 cells were transfected with pRNA-H1.1/Neo siRNA expression 
vector (GenScript Corp., USA) with or without a small DNA insert encoding a short hairpin 
RNA targeting p53 [16] and using Lipofectamine in combination with Plus Reagent 
(Invitrogen, Germany) according to the manufacturer’s recommendations. E6-expressing 
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A2780 human ovarian carcinoma cells and empty vector control cells were kindly provided 
by Dr. Michael Walton, Cancer Research UK Centre for Cancer Therapeutics, Institute of 
Cancer Research, Sutton, Surrey, UK. These cells were constructed as described previously 
[17] but using a pEFIRES-P vector system [18]. 
HCT116 cells were maintained in Dulbecco’s modified Eagle’s medium (DMEM) 
with Glutamax™ I, 1000mg/L D-glucose and sodium pyruvate (Invitrogen) and supplemented 
with 10% foetal bovine serum and 100 U/ml penicillin and 100 µg/ml streptomycin (Sigma 
Aldrich). A549 cells were grown similarly, but with geneticin (Invitrogen) (0.3mg/ml) instead 
of penicillin/streptomycin for selection of plasmid containing cells. A2780 cells were 
maintained under similar conditions to those for HCT116 cells with the addition of purimycin 
(Invitrogen) (0.6 µg/ml) for selection of plasmid containing cells. Cells were grown as 
adherent monolayers and sub-culturing performed every 72 h when cells were 80% confluent 
and incubated in a humidified 5% CO2 atmosphere at 37°C.  
BaP was obtained from Sigma Aldrich and BPDE was synthesised by the method of 
R.G. Harvey and P.P. Fu [19]. 3-Nitrobenzanthrone (3-NBA) was synthesised as previously  
reported by Arlt et al. [20]. For chemical exposure, cells were grown for 48 h until 70% 
confluent and then BaP, BPDE or 3-NBA dissolved in DMSO (Sigma Aldrich) were added. 
DMSO alone was added to control cultures and its volume kept at 0.2% of the total culture 
medium. Cells were harvested by trypsinisation and washed with PBS. 
 
Cell viability and DNA adduct measurement 
Cells were exposed to BaP (0.25-5 µM), BPDE (0.1-1 µM), 3-NBA (5 µM), or DMSO alone 
(controls) in duplicate and cell viability was measured as described previously [13]. Cells 
were spun down, and DNA was isolated by a standard phenol chloroform extraction method. 
DNA adducts were measured for DNA extracted from BaP and BPDE treated cells using the 
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nuclease P1 version of the 32P-postlabelling method as described previously [13]. For DNA 
prepared from cells treated with 3-NBA the butanol enrichment method was used to measure 
DNA adducts as described previously [20]. 
 
RNA extraction and cDNA synthesis for microarray analysis 
Cells were exposed to BaP (2.5 and 5 µM) for 6, 24 and 48 h, or BPDE (0.5 and 1 µM) for 2, 
6 and 24 h and control cells were treated with DMSO. All incubations were performed in 
triplicate. Cell pellets were collected and total RNA extracted using the Qiagen RNeasy Mini 
Kit protocol (RNeasy Mini Handbook, Qiagen, UK) and quantity and quality assessed as 
described [13]. Total RNA (4 µg) was reversed transcribed into cDNA and labelled with Cy3 
or Cy5 mono-reactive dyes (Amersham Biosciences, UK) using the Invitrogen Indirect cDNA 
Labelling Kit protocol (Invitrogen, UK) as described [13]. 
 
cDNA microarray hybridisations 
Gene expression analysis was performed using the Cancer Research UK DNA Microarray 
Facility (CRUKDMF) Human 22K Genome-Wide Array v1.0.0. The full probe list for this 
array can be found on the CRUKDMF website (http://www.icr.ac.uk/array/array.html). 
The majority of the clones have been sequence verified and are 800-2,000bp in length. The 
arrays were gridded onto Type 7* silanised slides (GE Healthcare, UK) and hybridisation, 
washing and scanning of the slides were performed as described previously [13]. RNA from 
exposed cells and time-matched vehicle-treated control cells were hybridised against each 
other for each dose and time-point from each triplicate biological experiment.  
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Microarray analysis 
Image analysis using GenePix Pro v-5.1 software (Axon Instruments, USA) and data 
normalisation and analysis were performed within GeneSpring v-7.2 as described previously 
[13]. Briefly, after Lowess normalisations and filtering out of unreliable data, triplicate 
biological replicates were averaged to identify genes with significantly (p < 0.05) altered 
expression by at least 1.4-fold. Log2 transformed data were used for any correlation 
(hierarchical clustering, principal components analysis [PCA]) or statistical algorithms (1-
Way ANOVA) performed within GeneSpring. 
The gene expression data discussed in this publication have been deposited in NCBI Gene 
Expression Omnibus (http://www.ncbi.nlm.nih.gov/geo/) (awaiting GEO accession number).  
 
 
Transient transfection of p53-targeted siRNA  
Approximately 3 x 105 HCT116 cells per well in a six-well plate in 2 ml medium containing 
10% fetal calf serum (FCS), but without antibiotics, were cultured for 24 h to give 40-60% 
confluence. Cells were transfected with an siRNA duplex (siGENOME Duplex D-003329-05, 
Dharmacon, Thermo Fisher Scientific, UK) that targets the mRNA sequence encoding p53. 
The siRNA was introduced into the cells by complex formation with DharmaFECT 1 lipid 
transfection reagent (Dharmacon) according to the recommendations of the manufacturer. 
Briefly, 200 pmol of siRNA oligonucleotides were mixed with 5 µl of DharmaFECT 1 in a 
final volume of 400 ml of serum-free medium. Complexes were allowed to form for 20 min at 
room temperature after which the samples were diluted in 1.6 ml of serum-containing 
medium, to give a final siRNA concentration of 100 nM, and then added directly to the cells 
after removal of old medium. Control cells were exposed to transfection reagent alone. Cells 
were harvested 24 -72 h after transfection for Western blot analysis. For chemical exposure, 
24 h after transfection, BaP or BPDE dissolved in DMSO was added to the cells. Cells were 
 8
harvested after 24 and 48 h exposure for Western blot and DNA adduct analysis. As an added 
control, cells were transfected with functional, non-targeting siRNA (siCONTROL™, 
Dharmacon) to confirm that knock-down of p53 transcript was specific to the p53-targeting 
siRNA molecule.  
 
Real-time quantitative PCR (RTqPCR) 
Reverse transcription-PCR was used to generate cDNA from total RNA for relative 
quantitation analysis using real-time fluorescent PCR on an ABI PRISM 7900HT Sequence 
Detection System (Applied Biosystems, UK) performed as previously described [13]. To 
detect the modulated expression of CYP1A1 and CYP1B1 20x Assays-On-DemandTM gene 
expression primers and probes (Applied Biosystems) were used (CYP1A1-Hs00153120_m1, 
CYP1B1-Hs00164383_m1). Relative gene expression was calculated using the comparative 
threshold cycle (CT) method as performed previously [13]. Transcript levels were compared 
between BaP-exposed cells and time-matched vehicle-treated control cells (calibrator sample) 
in order to measure gene induction.  
 
Western blot analysis 
Cells were exposed to BaP (2.5 µM) or BPDE (0.5 µM) for up to 48 h, and control cells were 
treated with DMSO. Cell pellets were collected and lysis and immunoblotting were performed 
as described previously [13]. Monoclonal antibody against p53 (Ab-6) was purchased from 
Calbiochem (Darmstadt, Germany) and diluted 1:5000. Detection of CDKN1A (p21) was by 
monoclonal antibody sc817 purchased from Santa Cruz Biotechnology (CA, USA), diluted 
1:500. For detection of CYP1A1 we used a polyclonal antibody (PAI-340) in a 1:500 dilution 
(Affinity BioReagents, Golden, CO, USA). Monoclonal antibody to detect GAPDH (6C5) 
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was purchased from Chemicon (Chemicon, Millipore, USA), diluted 1:2000 and used as a 
loading control. 
 
Flow cytometry 
Cells were exposed to 2.5 µM BaP, 0.5 µM BPDE or DMSO alone for up to 48 h. Harvested 
cells were fixed and stained with propidium iodide as described previously [13] in preparation 
for cell cycle analysis performed using a Beckman Coulter EPICS Elite ESP (Beckman 
Coulter, Buckinghamshire, UK) at 488 nm. The relative number of cells in each phase of the 
cell cycle was determined using Cylchred v1.0.2 and WinMidi v2.8 software 
(http://www.cardiff.ac.uk/medicine/haematology/cytonetuk/documents/software.htm). 
 
Caspase Glow® 3/7 assay 
The activities of caspase-3 and -7 were measured in HCT116 p53-WT and p53-null 
cells after exposure to 0.5 µM BPDE for up to 24 h in 96-well plates using a Caspase-Glo 
assay kit (Promega, Southampton, UK) and following the manufacturer’s instructions. 
Luminescent signal was detected using a Microtiter Plate Luminometer (DYNEX 
Technologies, Worthing, UK). Luminescence is proportional to the amount of caspase activity 
present and expressed as relative light units (RLU). 
 
RESULTS 
HCT116 p53-WT and p53-null gene expression analysis 
BaP-induced transcription: In total, the expression of 24 genes was modulated significantly 
by at least 1.4-fold in p53-WT cells and 21 in p53-null cells after BaP exposure 
(Supplementary Table 1). Seven genes were modulated in the same direction in both cell lines 
(Supplementary Figure 1A and Supplementary Table 1), suggesting that these genes are 
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altered by p53-independent mechanisms with a larger proportion of the expression changes 
being p53-dependent. When hierarchical clustering is performed on the data (Figure 1A) this 
difference is not so apparent and suggests that the gene expression profiles are relatively 
similar regardless of time, concentration, or p53 status. BaP had very subtle effects on gene 
expression in both cell lines with few genes exceeding a 2-fold change in expression. 
Induction of the xenobiotic metabolism gene NQO1 was independent of p53 status. A probe 
for CYP1A1 was not present on the microarrays but its induction by BaP in these cells was 
demonstrated by RTqPCR (Supplementary Table 4). Induction of CYP1B1 was not identified 
from the array data. The inability of the microarrays to detect changes in this transcript seems 
to be a common phenomenon and may be related to low basal expression levels in cells, as 
described in our previous study [13]. Up-regulation of CYP1B1 in HCT116 cells was 
however, detected by RTqPCR (Supplementary Table 4). 
Consistent with the subtle effects on gene expression, HCT116 cell viability was not 
significantly reduced by up to 5 µM BaP for up to 48 h exposure (Supplementary Figure 2A 
and B). Although an approximate 2-fold accumulation of p53 in the p53-WT cells was 
observed in response to BaP exposure (Figure 2A) a significant p53 gene expression response 
was not identified from the microarrays. Closer inspection of the expression data revealed that 
a key p53-regulated gene, CDKN1A, did have altered expression (1.4-fold) in p53-WT but not 
p53-null cells after 24 h exposure to 5 µM BaP, although it was not identified as significant. 
Whilst this observation was confirmed by RTqPCR (data not shown) it was not seen 
consistently at the protein level (Figure 2A).  
BPDE-induced transcription. The lack of a robust p53-gene expression response in the 
HCT116 cells after BaP exposure prompted us to investigate gene expression induced by the 
potent DNA binding metabolite of BaP, BPDE, in order to gain more information on the role 
of p53 in the BaP-gene expression response. Whilst BPDE exposure (up to 1 µM for up to 48 
 11
h) did not affect the viability of p53-null cells, a concentration-dependent reduction in 
viability of p53-WT cells of up to 40% was observed (Supplementary Figure 2C and D). 
BPDE exposure modulated significantly a total of 67 genes by at least 1.4-fold in p53-WT 
cells and 66 in p53-null cells (Supplementary Table 2) with an overlap of 25 genes altered in 
both cell lines (Supplementary Table 2 and Supplementary Figure 1B). As with the BaP-
induced expression profiles, hierarchical clustering revealed that the BPDE-induced gene 
expression profiles were not affected greatly by p53 status, but rather differences between the 
profiles were dependent on time of exposure to BPDE (Figure 1B). PCA confirmed these 
effects (Supplementary Figure 1C) and also showed that p53 status had a greater influence on 
the gene expression profiles after 24 h BPDE exposure. 1-Way ANOVA was performed on 
the list of all genes modulated by BPDE in the two cell lines (108 genes), which identified 22 
genes that were most significantly (p < 0.05) differentially expressed between the p53-WT 
and p53-null cells (Supplementary Table 3). This list includes p53-regulated genes, such as 
CDKN1A, DDB2, which were induced in p53-WT cells but not p53-null cells. In addition, 
tumour necrosis factor receptor (TNFR) genes, including p53 regulated FAS and TNFR10B, 
linked to apoptosis were up-regulated only in p53-WT cells.  
 
Affected biological processes 
To determine if any biological themes exist within the expression data of the HCT116 cells 
exposed to BPDE or BaP, Expression Analysis Systematic Explorer (EASE) analysis was 
performed to identify biological processes that are significantly over-represented (EASE score 
<0.05) in the gene lists when compared to their total representation on the microarrays. In 
concordance with the subtle effect that BaP had on gene expression in these cells, few 
biological processes were significantly over-represented in the BaP-gene lists and no overlap 
was observed between p53-WT and p53-null cells (not shown). Analysis of the BPDE-
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induced gene expression changes, however, revealed that apoptotic processes were 
significantly up-regulated in p53-WT cells but not in p53-null cells (Table 1), confirming that 
apoptotic signalling in response to BPDE exposure is dependent on p53. This is consistent 
with the cell viability data for these cells (Supplementary Figure 2C and D). Cell-cycle 
processes were up-regulated regardless of p53 status, although the genes linked to these 
processes differed between the p53-WT cells and p53-null cells with a number of genes 
linked to progression through mitosis up-regulated in p53-null cells (Table 1). Interestingly, 
processes linked to chromosome organisation were significantly affected through gene 
repression in both cell lines with down-regulation of HIST1H1C, HIST1H2AC, HIST1H2BJ, 
HIST1H3D and TAF6L. DNA repair processes were significantly up-regulated in p53-null 
cells, but not in p53-WT cells. 
 
DNA adduct analysis of HCT116 p53-WT and p53-null cells 
A time- and concentration-dependent increase in DNA adduct formation was observed in p53-
WT, but not in p53-null cells, exposed to up to 5 µM BaP for up to 48 h (Figure 3A). A 
striking observation was that BaP-induced DNA adduct levels were around 10-fold lower in 
p53-null cells relative to p53-WT cells. In contrast, similar or lower adduct levels in p53-WT 
cells relative to p53-null cells, were observed after exposure to BPDE (Figure 3B). This 
suggests that the difference in adduct levels in the two cell lines when exposed to BaP may be 
through a p53-dependent effect on the metabolic bioactivation of this compound. 
 
Cell cycle analysis of HCT116 p53-WT and p53-null cells 
To determine if p53 plays a role in the cell cycle effects induced by BaP and BPDE exposure, 
p53-WT and p53-null HCT116 cells were exposed to BaP (2.5 µM) or BPDE (0.5 µM) for up 
to 48 h and DNA content was measured by FACS analysis (Figure 4). In agreement with the 
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lack of cell cycle-related gene expression alterations in HCT116 cells exposed to BaP, this 
compound had no effect on their cell cycle parameters. Exposure to BPDE resulted in an 
accumulation of cells in S phase and a reduction of cells in G1 that was independent of p53 
status. After 48 h the number of exposed cells in S phase had almost returned to control 
levels. In p53-WT, but not p53-null cells, an arrest in G2 phase was evident at 48 h. 
 
Apoptotic activity of HCT116 p53-WT and p53-null cells 
BPDE had a greater effect on cell viability in p53-WT cells than in p53-null cells and, in 
agreement with this, apoptotic signalling was evident from the gene expression analysis of 
p53-WT cells, but not p53-null cells, exposed to BPDE. To confirm this differential response 
of the two cell lines to BPDE exposure, the activities of two key effector enzymes caspase-3 
and caspase-7 that are involved in apoptosis in mammalian cells, were measured by 
luminescence detection. This particular caspase assay was chosen as caspase-3 activation has 
been linked to BaP-induced apoptosis [21,22]. Figure 5 illustrates the level of luminescence 
detected in cells exposed to 0.5 and 1 µM BPDE for 6 and 24 h, which is proportional to the 
amount of caspase-3 and caspase-7 activity in the cells. While there is only a small difference 
in caspase activity after 6 h exposure in both cell lines there is a large increase in activity in 
p53-WT cells after 24 h exposure to 1 µM BPDE that is not seen in p53-null cells. This is 
consistent with the cell viability data where greatest loss of viability in p53-WT cells occurred 
after exposure to 1 µM BPDE (Supplementary Figure 2C). In these cells, the expression level 
of TNFR apoptosis signalling genes was greatest after 1 µM BPDE exposure, but 
predominantly after 6 h, not 24 h (Supplementary Table 3), indicating that apoptotic mRNA 
levels increase early followed by biological outcome at 24 h. 
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DNA adduct analysis in other cell line pairs differing in p53 status  
To determine if the apparent effect of loss of p53 on the activation of BaP and its DNA adduct 
forming capability was a consequence of the p53 knock-out procedure, two other cell line 
pairs differing in p53 status were investigated. A549 lung carcinoma cells stably expressing 
p53-targeting siRNA (with approximately 50% reduction in p53 protein expression, Figure 
2C) and A2780 ovarian carcinoma cells stably expressing either of two different E6 clones 
(with approximately 70% reduction in p53 protein expression, Figure 2D) were compared 
against empty vector control cells. E6 is a viral oncoprotein that can complex with p53 and 
target it for degradation, the result of which can be equivalent to inactivating p53 by mutation 
[23]. In addition, we silenced the expression of p53 transiently with siRNA in the HCT116 
p53-WT cells and compared them with mock-transfected cells. A reduction of approximately 
80% in p53 protein expression was achieved in these cells (Figure 2B) specific to the p53 
siRNA, as confirmed by parallel transfection with a functional, non-targeting siRNA control 
(not shown). Reduction of CDKN1A was observed in all cells with reduced p53 expression 
(Figure 2A-D), confirming the p53 status of the cells. 
DNA adduct levels were measured in all cell lines after exposure to BaP or BPDE for 
24 and 48 h (Figure 6A-D). Significantly lower adduct levels were detected in all cell lines 
with reduced p53 expression, relative to their controls, after 48 h exposure to BaP. This was 
also observed at 24 h for the HCT116 with complete p53 knock-out and for the A2780 cells 
with knocked-down p53 expression. This provides evidence that the observed effects on BaP-
induced DNA adduct formation are not artefacts of the cells’ manipulation, but are genuinely 
p53-dependent. In contrast, BPDE exposure of the cells, in the majority of cases, resulted in 
similar DNA adduct levels regardless of p53 status (Figure 6) suggesting that the effect seen 
with BaP is not related to DNA repair, but to the metabolic activation of BaP. Interestingly, 
exposure to 3-NBA, a nitro-PAH that also requires metabolic activation to form DNA adducts 
 15
[24-26], resulted in similar adduct levels in p53-WT and p53-null cells (Figure 6). 
Bioactivation of 3-NBA is catalysed primarily by cytosolic nitroreductases such as NQO1 
rather than cytochrome P450 (CYP) enzymes [25,26] indicating that basal levels of p53 might 
be linked to the expression of CYP enzymes, such as CYP1A1 and/or CYP1B1. To determine 
if loss of p53 affects the levels of key enzymes involved in the bioactivation of BaP, the 
induction of CYP1A1 and CYP1B1 expression was assessed by RTqPCR (Supplementary 
Table 4). Whilst an approximate 6-fold lower induction of these transcripts was observed in 
HCT116 p53-null cells relative to p53-WT cells, equal induction of these genes was seen for 
the other cell line pairs. In addition, no difference in the basal or induction levels of CYP1A1 
protein, as assessed by Western blot, was observed between the HCT116 p53-WT and p53-
null cells (data not shown). 
 
DISCUSSION 
The tumour suppressor protein p53 protects cells from genotoxic stress by activating cellular 
processes such as cell cycle inhibition, DNA repair and apoptosis [2,5]. The importance of 
this protein is highlighted by the fact that it is mutated in approximately 50% of human 
cancers [1] and this figure increases to 60% for lung cancers [27]. There are examples of 
correlation between sites of carcinogen-DNA damage in the p53 gene in cells in culture and 
the sites of p53 mutations in human tumours [7-9], strongly indicating that this DNA damage 
is directly linked to carcinogenesis. Cellular accumulation of p53 in response to PAH 
exposure has been observed in many studies and recently we identified p53 as an important 
component of BaP-induced transcriptional responses in human cell lines [13]. To further 
understand the role of p53 in the cellular response to BaP exposure we have compared the 
transcriptional responses to BaP or BPDE in human cells that differ in p53 status.  
 16
 
Gene expression analysis of HCT116 cells 
BaP had very subtle effects on HCT116 cells, with little evidence of a p53 response. 
This may be due to the levels of DNA damage not being high enough to elicit such a 
response. Exposure to BPDE resulted in greater transcriptional signatures that were most 
distinguishable by duration of exposure. A small sub-set of p53-dependent gene expression 
changes were identified and p53 status of the cells was most apparent after the longer 
exposure time of 24 h, which may be a result of downstream gene expression alterations, 
dependent on p53 activation, coming into effect over time. Included in the p53-dependent 
gene expression signature were known p53-regulated genes, including CDKN1A and DDB2 
that were also identified by Amundson et al. [14] as discriminating p53 status in TK6 cells.  
Amundson’s study [14] investigated the participation of p53 in gene expression 
signatures induced by toxic stress in TK6 cells differing in p53 status. Although they 
identified a small p53-dependent signature for genotoxic agents, all profiles were largely 
independent of p53 status, but were, however, distinguishable by mechanistic differences 
between the stresses. Similarly Park et al., who analysed the expression of a relatively small 
set of genes in cells exposed to γ-irradiation, UV, doxorubicin and cisplatin did not identify 
any p53-dependent expression. The current study extends these studies to consider the 
important class of PAHs and also shows that expression profiles induced by BaP or BPDE 
exposure are largely p53-independent, although a sub-set of p53-dependent expression was 
identified. Several PAH compounds, including BaP, have been shown to induce apoptosis in 
vitro [28-30], a process in which p53 plays an important role [28]. The expression of three 
genes, FAS, TNFRSF10B and TNFRSF10D, which encode members of the tumour necrosis 
factor receptor family of death receptors, was identified as dependent on p53 in cells exposed 
to BPDE in this study. Upon ligand binding these death receptors are capable of signalling for 
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apoptosis through a ‘death domain’ contained within their intracellular portion and 
transactivation of these receptors by p53 has been shown to mediate apoptosis in vitro 
[31,32]. The effect of BPDE on cell viability in HCT116 cells may be through signalling of 
these receptors that are up-regulated in a p53-dependent manner. Apoptotic signalling was 
also seen as p53-dependent at the level of affected biological processes. Functional analysis of 
the cells also confirmed this response with a greater increase in apoptotic signalling, as 
measured by caspase activity, observed in the cells expressing p53. We have also seen the 
induction of members of these death receptors in two other cell lines, MCF-7 and HepG2, 
after BPDE exposure [33], indicating that this is an important p53-dependent cellular 
response to this compound in vitro.  
Previously we detected the repression of histone genes in response to BaP exposure in 
MCF-7 and HepG2 cells and histone expression levels showed a strong inverse correlation 
with DNA adduct formation in MCF-7 cells [13]. BPDE exposure of HCT116 cells also led to 
the repression of a number of histone genes and, interestingly, this effect was independent of 
p53 status. It is therefore likely that regulation of histone gene expression is important in the 
cellular response to PAH exposure. The expression of histone genes is tightly coupled to 
DNA synthesis [34], the delay of which is evident in cells exposed to BaP that undergo an 
accumulation in S phase of the cell cycle [13,35,36]. The repression of histone expression has 
also been observed in response to ionising radiation-induced DNA damage [37,38] and in 
yeast cells exposed to aflatoxin B1 that were also seen to arrest in S phase [39]. The 
conservation of this response across species suggests that this cellular response is important in 
maintaining DNA integrity after genotoxic insult. In this study we have shown that, consistent 
with histone gene repression, the accumulation of cells in S phase after BPDE exposure is 
also independent of p53 status, further validating the link between these two events. This 
stealth property of cells to evade a protective G1 arrest initiated by p53 activation, after BaP 
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or BPDE exposure, has been seen in response to other PAHs [40,41] and has also been 
observed in p53-deficient human cells exposed to aflatoxin B1 [42], consistent with our 
finding that this effect is independent of p53. It has been suggested that the ability of cells to 
overcome G1 arrest and accumulate in S phase leaves them more susceptible to DNA damage 
and transformation [36,43] and that lack of G1 arrest is through inability to induce the 
expression of the potent G1/G2 cell cycle inhibitor, CDKN1A [43]. In this study, however, 
we saw accumulation of CDKN1A protein in p53-WT cells at time-points at which S phase 
accumulation was also observed, but not G1 arrest. G2 arrest was also evident in p53-WT 
cells, which may be a result of p53-dependent expression of CDKN1A [15] coming into play 
in these cells as an added protective mechanism against DNA damage. In addition, a large 
number of genes linked to the mitotic phase of the cell cycle were induced in p53-null cells 
but not p53-WT cells, suggesting that p53 is involved in the repression of these genes thus 
preventing progression into mitosis after S phase arrest.  
 
The effect of p53 on DNA adduct formation 
DNA adduct analysis of HCT116 cells exposed to BaP revealed that adduct levels 
were significantly lower in cells not expressing p53. This was not seen after BPDE exposure 
suggesting that basal levels of p53 are linked to the metabolic activation of BaP. The gene 
expression data suggest that off-target effects of the p53 knock-out procedure by homologous 
recombination are minimal at the gene expression level. The observed effect of loss of p53 on 
BaP metabolism and DNA adduct formation in HCT116 cells was confirmed through the 
investigation of other cell lines with partial knock-down of p53 by different methods, which 
also saw lower DNA adduct levels in cells with lower p53 levels. The difference in adduct 
levels in cells with partial loss of p53 was smaller than that observed in cells with no p53 
expression, suggesting that the effect is related to the level of p53 expression. The 
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observations made in this in-vitro study are in contrast to in-vivo studies in which loss of p53 
results in increased DNA adduct levels and tumour formation [11,12,44]. Higher induction of 
CYP1A1 and CYP1B1 expression could only explain the difference in BaP metabolism in the 
HCT116 cells with complete loss of p53, although this was not observed at the protein level. 
Further investigation of levels of other key xenobiotic metabolism enzymes and their 
activities, together with global gene expression analyses of the additional cell lines, need to be 
carried out.  
 
Conclusion 
We have characterised cellular responses to BaP and its metabolite BPDE and gained 
greater insight into the role of p53 in these responses. Although a p53-dependent signature 
was identified, many genes were altered independently of p53. Whilst apoptotic responses 
have been identified as dependent on p53, early cell-cycle effects were seen to be independent 
of this tumour suppressor. The effect of loss of p53 on the metabolic activation of BaP in vitro 
was unexpected and requires further investigation.  
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Table 1. Biological processes significantly (EASE Score < 0.05) over-represented within the 
gene expression profiles induced after BPDE exposure in HCT116 p53-WT and p53-null 
cells. 
 Biological Process p53-WT p53-null 
 
Cell cycle/cell proliferation 
 
BTG3, CDC2, CDKN1A, PCNA, RPS27L, 
RRM2, TOB1 1↑ 
 
CCNA2, CDC2, CDC6, MAD2L1, MCM3, 
MCM4, PCNA, PPP2CA, RBBP4, RBBP6, 
RRM2, SMC1L1, TOB1, UBE2C ↑ 
 
M phase of mitotic cell cycle 
   
CCNA2, CDC2, MAD2L1, PPP2CA, SMC1L1, 
UBE2C ↑ 
 
DNA replication/S phase of 
mitotic cell cycle 
   
CDC6, MCM3, MCM4, PCNA, PPP2CA, 
RBBP4, RRM2, SMC1L1, UBE2C, UNG ↑ 
Apoptosis CDKN1A, TNFRSF10B, TNFRSF6 ↑   
 
Response to DNA damage 
stimulus 
   
PCNA, RBBP4, SMC1L1, TNKS2, UBE2C, 
UNG ↑ 
DNA repair   PCNA, RBBP4, SMC1L1, UBE2C, UNG ↑ 
Cytokinesis   CCNA2, CDC2, CDC6, SMC1L1, UBE2C ↑ 
 
Cell growth and/or maintenance 
   
CCNA2, CDC2, CDC6, K-ALPHA-1, 
MAD2L1, MCM3, MCM4, PCNA, PPP2CA, 
RBBP4, RBBP6, RRM2, SMC1L1, STMN1, 
TNKS2, TOB1, UBE2C ↑  
 
AREG, EREG, HIST1H1C, HIST1H2AC, 
HIST1H2BJ, HIST1H3D, IGFBP3, PLAU, 
SLC38A2, TAF6L, XPO1 ↓ 
Microtubule-based process   K-ALPHA-1, PPP2CA, SMC1L1 ↑ 
 
Assembly/maintenance of 
chromatin 
 
HIST1H1C, HIST1H2AC, HIST1H2BJ, 
HIST1H3D, TAF6L ↓ 
 
HIST1H1C, HIST1H2AC, HIST1H2BJ, 
HIST1H3D, TAF6L ↓ 
 
Cell organisation and biogenesis 
 
HIST1H1C, HIST1H2AC, HIST1H2BJ, 
HIST1H3D, TAF6L, TTK ↓ 
 
HIST1H1C, HIST1H2AC, HIST1H2BJ, 
HIST1H3D, TAF6L ↓ 
 
DNA metabolism 
 
FOS, HIST1H1C, HIST1H2AC, HIST1H2BJ, 
HIST1H3D, NPAS2, SFPQ, SLC38A2, 
SMURF2, TAF6L, XRCC4 ↓ 
  
 
Nucleic acid metabolism 
   
HIST1H1C, HIST1H2AC, HIST1H2BJ, 
HIST1H3D, SLC38A2, SMURF2, TAF6L, 
TCF7L2, TEAD1 ↓ 
 
Regulation of transcription 
   
HIST1H1C, HIST1H2BJ, SLC38A2, SMURF2, 
TAF6L, TCF7L2, TEAD1 ↓ 
1↑ up-regulated expression ↓ down-regulated expression 
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TITLES AND LEGENDS TO FIGURES  
Figure 1. Hierarchical cluster analysis of HCT116 cells exposed to BaP and BPDE. 
Hierarchical clustering was performed on all experimental conditions using genes modulated 
in at least one of the cell lines after (A) BaP exposure (38 genes) and (B) BPDE exposure 
(108 genes).  
 
Figure 2. Western blot analysis of p53 and CDKN1A protein expression in cells differing 
in p53 status exposed to BaP or BPDE. 
(A) HCT116 control cells and those with knock-out of p53 by homologous recombination, 
(B) HCT116 control mock transfected cells and those transfected with p53-targeting siRNA 
molecule, (C) A549 control cells expressing empty vector or cells stably expressing p53-
targeting shRNA plasmid and (D) A2780 control cells expressing empty vector or cells stably 
expressing either of two E6 clones were exposed to 2.5 µM BaP or 0.5 µM BPDE, and 
protein extracted for Western blot analysis of p53 and CDKN1A protein levels. GAPDH 
protein expression, was used as loading control. 
 
Figure 3. DNA adduct levels detected in HCT116 p53-WT and p53-null cells after BaP 
or BPDE exposure. 
Cells were exposed to (A) up to 5 µM BaP or (B) up to 1 µM BPDE and harvested after the 
times indicated for DNA adduct analysis by 32P-postlabelling. The values are the mean ± 
range of duplicate cell incubations; each DNA sample was determined by two post-labelled 
analyses.  
Statistical significance of differences between the adduct levels of p53-WT and p53-null cells 
was determined by a Student’s t-test.  
* p<0.01, # p<0.05. 
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Figure 4. Effects of BaP and BPDE on cell cycle in HCT116 p53-WT and p53-null cells. 
The stacked bar-chart shows the percentage distribution of cell cycle parameters after 
exposure of HCT116 cells to 2.5 µM BaP, 0.5 µM BPDE or DMSO as control for the times 
indicated. The histograms are representative of two independent experiments for which the 
standard deviation was never greater than 5%. 
 
Figure 5. Caspase 3/7 activities in HCT116 p53-WT and p53-null cells exposed to BPDE. 
The activities of caspase-3 and caspase-7 were measured by luminescence detection in cells 
after exposure to BPDE (0.5 and 1 µM) for 6 and 24 h. The number of relative light units 
(RLU) is proportional to the amount of caspase activity. The values are the mean ± S.D. of 
three independent experiments.  
 
Figure 6. DNA adduct analysis of cell lines pairs with complete or partial knock-down of 
p53. 
DNA adduct levels were measured in (A) HCT116 control cells and those with knock-out of 
p53 by homologous recombination, (B) HCT116 control mock transfected cells and those 
transfected with p53-targeting siRNA molecule, (C) A549 control cells expressing empty 
vector or cells stably expressing p53-targeting shRNA and (D) A2780 control cells expressing 
empty vector or cells stably expressing either of two E6 clones after exposure to 2.5 µM BaP, 
0.5 µM BPDE or 5 µM 3-NBA for 24 and 48 h. The values are the mean ± range of duplicate 
cell incubations; each DNA sample was determined by two postlabelled analyses.  
Statistical significance of differences between the adduct levels of control and p53 knock-
down cells was determined by a Student’s t-test.  
* p<0.01, # p<0.05. 
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